ArticleFrontiers in oncology2022

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II-III gastroesophageal junction adenocarcinoma: A large population-based cohort study.

Zhichao Zuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.